Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines

被引：68

作者：

Wang, YD ^{[1
]}

Miller, K ^{[1
]}

Boschelli, DH ^{[1
]}

Ye, F ^{[1
]}

Wu, BQ ^{[1
]}

Floyd, MB ^{[1
]}

Powell, DW ^{[1
]}

Wissner, A ^{[1
]}

Weber, JM ^{[1
]}

Boschelli, F ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Chem Sci & Oncol, Pearl River, NY 10965 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2000年 / 10卷 / 21期

关键词：

D O I：

10.1016/S0960-894X(00)00493-5

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：2477 / 2480

页数：4

共 50 条

[1] 4-ANILINOQUINAZOLINES - A NEW CLASS OF TYROSINE KINASE INHIBITORS
BARKER, AJ
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 142 - MEDI
[2] Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors Focus on 4-Anilinoquinazolines
Scheffler, Matthias
Di Gion, Paola
Doroshyenko, Oxana
Wolf, Juergen
Fuhr, Uwe
CLINICAL PHARMACOKINETICS, 2011, 50 (06) : 371 - 403
[3] Inhibition of Src kinase activity by a series of 4-anilino-3-cyanoquinolines.
Ye, F
Boschelli, DH
Wang, D
Wu, BQ
Zhang, N
Powell, DW
Wissner, A
Boschelli, F
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 220 : U545 - U546
[4] Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsFocus on 4-Anilinoquinazolines
Matthias Scheffler
Paola Di Gion
Oxana Doroshyenko
Jürgen Wolf
Uwe Fuhr
Clinical Pharmacokinetics, 2011, 50 : 371 - 403
[5] Novel 4-anilinoquinazolines with C-6 carbon-linked side chains:: Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors
Hennequin, LFA
Ballard, P
Boyle, FT
Delouvrié, B
Ellston, RPA
Halsall, CT
Harris, CS
Hudson, K
Kendrew, J
Pearse, JE
Ross, HS
Smith, P
Vincent, JL
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) : 2672 - 2676
[6] Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors
Li, Dong-Dong
Fang, Fei
Li, Jing-Ran
Du, Qian-Ru
Sun, Jian
Gong, Hai-Bin
Zhu, Hai-Liang
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (18) : 5870 - 5875
[7] Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
Wakeling, AE
Barker, AJ
Davies, DH
Brown, DS
Green, LR
Cartlidge, SA
Woodburn, JR
BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) : 67 - 73
[8] Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro
Denny, WA
Rewcastle, GW
Bridges, AJ
Fry, DW
Kraker, AJ
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 (05) : 424 - 427
[9] Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors
Hennequin, LF
Stokes, ESE
Thomas, AP
Johnstone, C
Plé, PA
Ogilvie, DJ
Dukes, M
Wedge, SR
Kendrew, J
Curwen, JO
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) : 1300 - 1312
[10] Structure-activity relationship of 7-aryl-2-anilino-pyrrolopyrimidines as Mer and Axl tyrosine kinase inhibitors
Chung, Shin Hyuck
Park, Jiwon
Lee, Jung Wuk
Song, Jiho
Jung, Danbee
Min, Kyung Hoon
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1822 - 1833

← 1 2 3 4 5 →